Biodesix (BDSX) Projected to Announce Quarterly Earnings on Thursday

by · The Markets Daily

Biodesix (NASDAQ:BDSX – Get Free Report) is anticipated to announce its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Biodesix to post earnings of ($0.75) per share and revenue of $27.49 million for the quarter. Interested persons may review the information on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Biodesix (NASDAQ:BDSX – Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.71) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.19. The business had revenue of $26.86 million during the quarter, compared to analyst estimates of $26.03 million. Biodesix had a negative net margin of 26.97% and a negative return on equity of 788.19%. On average, analysts expect Biodesix to post ($2.68) EPS for the current fiscal year and ($1.66) EPS for the next fiscal year.

Biodesix Stock Performance

BDSX stock opened at $21.05 on Wednesday. The company has a debt-to-equity ratio of 5.12, a quick ratio of 2.85 and a current ratio of 2.85. The stock has a market cap of $222.08 million, a P/E ratio of -6.64 and a beta of 0.65. The firm has a 50 day simple moving average of $26.28 and a 200 day simple moving average of $18.77. Biodesix has a 52 week low of $5.26 and a 52 week high of $31.97.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. TD Cowen reiterated a “buy” rating and issued a $40.00 price objective (up from $30.00) on shares of Biodesix in a research note on Tuesday, October 13th. Weiss Ratings upgraded shares of Biodesix from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, September 8th. HC Wainwright reissued a “buy” rating on shares of Biodesix in a research note on Thursday, October 22nd. Finally, Canaccord Genuity Group lifted their target price on shares of Biodesix from $27.00 to $35.00 and gave the company a “buy” rating in a research note on Monday, August 10th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Biodesix has an average rating of “Moderate Buy” and an average price target of $36.25.

Get Our Latest Stock Analysis on Biodesix

Insiders Place Their Bets

In other news, Director Jack Schuler purchased 15,000 shares of the business’s stock in a transaction dated Wednesday, August 12th. The stock was bought at an average cost of $24.47 per share, with a total value of $367,050.00. Following the purchase, the director directly owned 555,810 shares of the company’s stock, valued at approximately $13,600,670.70. This trade represents a 2.77% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Over the last quarter, insiders bought 42,600 shares of company stock valued at $1,033,062. Corporate insiders own 23.20% of the company’s stock.

About Biodesix

(Get Free Report)

Biodesix, Inc is a data-driven diagnostic solutions company focused on improving the diagnosis and treatment of lung diseases, including lung cancer. The company combines proprietary molecular diagnostic technologies, clinical data, and artificial intelligence to help physicians assess disease risk and make more informed treatment decisions.

Its offerings include blood-based tests designed to help evaluate indeterminate pulmonary nodules, identify patients who may be at higher risk of lung cancer, and support treatment selection and monitoring.

Read More